Compare Smith & Nephew plc (SNN) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Vanguard Total International Stock Index Fund ETF — how do they compare? Smith & Nephew plc trades at $29.62 (market cap $12.54B), while Vanguard Total International Stock Index Fund ETF trades at $87.69. The key difference: Smith & Nephew plc pays a 2.65% dividend while Vanguard Total International Stock Index Fund ETF pays none, and Vanguard Total International Stock Index Fund ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| SNN | VXUS | |
|---|---|---|
Market Cap | $12.54B | — |
Sector | Health | Sector/Thematic |
52-Week High | $38.70 | $87.21 |
52-Week Low | $28.73 | $70.87 |
Enterprise Value | $15.57B | — |
Dividend Yield | 2.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $30.08, down 0.1% with bearish technical signals. The company reported mixed Q2 2026 results with revenue growth below expectations, leading to a reduced full-year outlook. Fundamentals show strong profitability with 10.1% net margin and improving cash flow trends, though recent earnings misses have tempered sentiment.
Outlook remains cautious with analyst consensus at Hold (65% of coverage). Near-term risks include U.S. orthopedics weakness and competitive pressures, offset by robotics innovation and value-based care expansion. The stock offers stable fundamentals but faces execution challenges in key markets.
VXUS, the Vanguard Total International Stock ETF, trades at $87.72, up 1.02% on the day, with a bullish technical signal driven by strong moving average alignment. Recent news highlights its role in global diversification, with a 27.82% total return over the past year noted by Seeking Alpha on August 8, 2026. The ETF offers exposure to over 8,700 non-U.S. stocks, attracting institutional interest, though RSI levels suggest potential near-term overbought conditions.
The outlook for VXUS is supported by its valuation discount to U.S. equities and broad diversification benefits, but risks include global economic sensitivity and inflationary pressures. Analyst sentiment is mixed, with some advocating buys for long-term portfolios while others caution on growth-inflation dynamics. Institutional holdings have increased, reflecting confidence in international market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
